Gene:
KIF6
kinesin family member 6

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs20455 2155T>C, 39265078A>G, 39325078A>G, KIF6:Trp719Arg, Trp719Arg
A > G
Missense
Trp719Arg
No VIP available No Clinical Annotations available VA
rs9462535 2181-1490G>T, 39255792C>A, 39315792C>A
C > A
Intronic
No VIP available No Clinical Annotations available VA
rs9471077 2428+2743T>C, 39248742A>G, 39308742A>G
A > G
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  None
Alternate Symbols:  DKFZp451I2418; MGC33317; dJ1043E3.1; dJ137F1.4; dJ188D3.1
PharmGKB Accession Id: PA134920075

Details

Cytogenetic Location: chr6 : p21.2 - p21.2
GP mRNA Boundary: chr6 : 39302876 - 39693181
GP Gene Boundary: chr6 : 39299876 - 39703181
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Curated Information ?

Publications related to KIF6: 9

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group. Journal of the American Heart Association. 2012. Musunuru Kiran, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. Journal of the American College of Cardiology. 2011. Hopewell Jemma C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Human genetics. 2011. Li Yonghong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. The Journal of molecular diagnostics : JMD. 2010. Pratt Victoria M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. The American journal of cardiology. 2010. Li Yonghong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 2010. Iakoubova Olga A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. The American journal of cardiology. 2010. Shiffman Dov, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. Journal of the American College of Cardiology. 2008. Iakoubova Olga A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. Journal of the American College of Cardiology. 2008. Iakoubova Olga A, et al. PubMed

LinkOuts

Entrez Gene:
221458
RefSeq RNA:
NM_145027
RefSeq Protein:
NP_659464
RefSeq DNA:
AC_000049
AC_000138
NC_000006
NT_007592
NW_001838980
NW_923073
UniProtKB:
KIF6_HUMAN (Q6ZMV9)
Ensembl:
ENSG00000164627
GeneCard:
KIF6
ALFRED:
LO015136Q
HuGE:
KIF6
ModBase:
Q6ZMV9
HumanCyc Gene:
HS15221
HGNC:
21202

Common Searches